Information  X 
Enter a valid email address

Celltech Group PLC (154)

  Print   

Friday 18 July, 2003

Celltech Group PLC

Offer Update

Celltech Group PLC
18 July 2003

  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA OR
                                     JAPAN



                                                                    18 July 2003

                         CELLTECH GROUP PLC (CELLTECH)

                 CASH OFFER FOR OXFORD GLYCOSCIENCES PLC (OGS)




On 26 February 2003, Celltech and (outside the United States) JPMorgan on its
behalf, announced a cash offer for the entire issued and to be issued share
capital of OGS.

Celltech announced on 16 April 2003 that the Offer had become unconditional in
all respects and on 4 June 2003 announced that it had commenced the procedure
for the compulsory acquisition of the remaining OGS Shares under the Companies
Act 1985 (the Act).


Celltech announces that on 18 July 2003, pursuant to section 429 of the Act, it
completed the compulsory acquisition of those OGS Shares for which acceptances
of the Offer had not been received. As a result of the compulsory acquisition,
Celltech has acquired 100 per cent. of the issued OGS Shares.


Application has already been made to the UK Listing Authority (the UKLA) to
cancel the listing of the OGS Shares on the Official List of UKLA and to the
London Stock Exchange plc (the LSE) to cancel the admission to trading of the
OGS Shares on the LSE with effect from 8.00 a.m. on 21 July 2003.


Enquiries:

For further information contact:
Celltech Group plc                                Telephone: +44 (0)1753 534 655
Dr Goran Ando, CEO
Peter Allen, Deputy CEO and CFO
Richard Bungay, Director of Corporate Communications
JPMorgan                                         Telephone: +44 (0)20 7742 4000
David Kellett, Associate



Terms defined in the Offer Document have the same meaning when used in this
announcement.



The Directors of Celltech accept responsibility for the information contained in
this announcement, and, to the best of their knowledge and belief (having taken
all reasonable care to ensure such is the case), the information contained in
this announcement is in accordance with the facts and does not omit anything
likely to affect the import of such information.



J.P. Morgan plc, which is regulated in the United Kingdom by the Financial
Services Authority, is acting for Celltech and for no one else in connection
with the Offer and will not be responsible to anyone other than Celltech for
providing the protections afforded to customers of JPMorgan or for providing
advice in relation to the Offer, the contents of the Offer Document or any
transaction or arrangement referred to therein.


This announcement has been approved by J.P.Morgan plc for the purpose of section
21 of the Financial Services and Markets Act 2000 only.



END


                      This information is provided by RNS
            The company news service from the London Stock Exchange                                                                                                                                                                      

a d v e r t i s e m e n t